Arne van Schanke is Senior Director, Early Development, and has been with Certara since 2014. Arne has two decades of experience in the pharmaceutical industry, including roles at MSD, Organon, and for numerous biotech companies via Certara working phases from drug discovery to late-phase development. Arne is a pragmatic biomedical scientist who evolved from biochemical interactions and cancer research into drug metabolism and pharmacokinetics expert and translational modeler working in a broad array of indications including Oncology, Virology, and Fertility, and modalities from small molecules and peptides to antibody drug conjugates and oligonucleotides.